Summary A phase 11 trial of continuous oral therapy with UFT, a combination of uracil and the 5-fluorouracil analogue 1-(2-tetrahydrofuryl)-5-fluorouracil (Futraful, Ftorafur), was conducted in 40 patients with advanced colorectal cancer and 18 patients with advanced gastric cancer. Six partial responses were seen in the 36 evaluable patients with colorectal cancer (response rate 16.6%; 95% confidence limits 6.4-32.8%), and one partial response was seen in the 16 evaluable patients with gastric cancer (response rate 6%; 95% confidence limits 0.27-30.2%). The overall toxicity of the treatment was low, and all patients were treated as outpatients. The results suggest that oral UFT has comparable activity to standard regimes of 5-fluorouracil, and because of the convenience of oral administration is a useful therapy in the management of patients with advanced colorectal cancer.
The fluoropyrimidines, particularly 5-fluorouracil (5-FU), have been widely used as single agents in the therapy of advanced gastric and colonic cancer. The reported response rates for these tumours with standard schedules of 5-FU generally range from 7 to 25% (Moertel, 1973; Earl et al., 1984) . The response to 5-FU appears to be dose and schedule dependant (Ansfield et al., 1977) , and on theoretical grounds, it would seem that prolonging exposure of tumour cells to 5-FU, would allow the drug to kill more tumour cells as they enter S phase (Drewinko et al., 1985) . Two limitations to the effective use of 5-FU are its short half-life (approximately 10 min), and its propensity to cause myelotoxicity at higher doses. Recent approaches that have been taken to enhance its effectiveness bearing these theoretical limitations in mind, are the use of continuous infusion therapy (Lokich et al., 1989) , and combining 5-FU with high dose folinic acid (Erlichman et al., 1988) .
Another approach to improve the anti-tumour effects of fluoropyrimidines that has been described in in vitro test systems and experimental animal models, is the concomitant use of purine and pyrimidine nucleotides with fluoropyrimidines, e.g. the 5-FU analogue, 1-(2-tetrahydrofuryl)-5-fluorouracil (Futraful, Ftorafur) (Fujii et al., 1978 (Fujii et al., , 1979 ). An enhanced antitumour effect is seen with Futraful if uracil is concomitantly administered in a molar ratio of 1:4 (Futraful:uracil). The mechanism of this potentiation is thought to be due to the inhibitory effect of uracil on the degradation of 5-FU released as a consequence of Futraful metabolism. The inhibitory effect of uracil on 5-fluorouracil metabolism seems to be more marked in tumours compared to normal tissues. Animal (Fujii et al., 1980) , and human studies (Taguchi et al., 1978) , have shown that the tumour levels of 5-fluorouracil achieved after concomitant administration of uracil with Futraful are higher than levels in peripheral blood and that these are sustained for longer periods in tumour cells.
Futraful has attracted interest not only because of its lower myelotoxicity, but also because of its greater bioavailability after oral administration in comparison to 5-fluorouracil. It is metabolised to 5-fluorouracil and at least four other compounds (Blokhina et al., 1972; Au et al., 1979) , which may also contribute to its cytotoxic effects. The parent compound has a long half-life, ranging from 6 to 16 h, and may therefore act as a depot preparation of 5-fluorouracil. In two studies, comparable plasma levels of 5-fluorouracil over a period of 24 h were obtained following a 30 min infusion of Futraful (2 gm-2), and a continuous infusion of 5-fluorouracil (30 mg kg-', 24 h-') (Anttila et al., 1983; Chabner, 1982) .
These studies suggest that combined administration of uracil with Futraful might not only enhance antitumour activity, but also decrease systemic side effects. The results of a phase II trial of continuous daily administration of an oral preparation of Futraful and uracil (molar ratio 1:4), known as UFT, in patients with advanced colorectal and gastric carcinoma are reported here.
Methods
Drug administration Phase I trials of UFT have established that the maximum tolerated dose is in the range of 12 mg kg-' day-' (Taguchi et al., 1990) . In this trial the dose given to patients was calculated on this basis, and given as three divided doses daily. In practice most patients received 600 mg UFT day-' (200 mg three times a day). Treatment was continued for at least three months, unless there was unequivocal disease progression or toxicity prior to formal radiological assessment of disease.
Patients
The inclusion criteria for patients were as follows. (1) The details of the patients entered into the study are shown in Table I . (Wadler et al., 1989) . These regimes, although leading to complete responses in a small number of patients, are associated with appreciable toxicity, and require parenteral administration. The results presented in this paper suggest that oral UFT is a relatively non-toxic chemotherapeutic agent that has some efficacy in the treatment of metastatic colorectal cancer, but a dissapointingly low rate of response in gastric cancer.
The observed response rate of 16.6% (95% confidence limits 6.4-32.8%), accurately documented with CT scanning of measurable disease, is within the range reported for standard bolus regimes of 5-FU, but lower than that observed with infusional 5-FU (Lokich et al., 1989) , or the combination of 5-FU with high dose folinic acid (Erlichman et al., 1988) . Although these regimes have led to complete remissions in a very small number of patients, they are associated with greater toxicity than UFT and for the majority of patients have no impact on survival. There is therefore still a need for a chemotherapeutic agent, which can be given with palliative intent, with a significant antitumour effect, ease of administration, and relatively few side effects. This study suggests that oral administration of UFT may fulfil some of the above criteria.
